414 related articles for article (PubMed ID: 8769219)
1. Conversion from cyclosporine to Neoral in pediatric recipients for kidney, liver, and heart transplantation.
Holmberg C; Laine J; Jalanko H; Leijala M; Hoppu K
Transplant Proc; 1996 Aug; 28(4):2262-3. PubMed ID: 8769219
[No Abstract] [Full Text] [Related]
2. Cyclosporine neoral pharmacokinetics in kidney and heart transplant patients.
Schiavelli R; Sgrosso JL; Sabbatiello R; Castro C; Ahualli L; Pattin M; Vazquez MC
Transplant Proc; 1996 Dec; 28(6):3343-4. PubMed ID: 8962299
[No Abstract] [Full Text] [Related]
3. Conversion from Sandimmune to Neoral and induction therapy with Neoral in pediatric renal transplant recipients.
Hoyer PF; Boekenkamp A; Vester U; Offner G; Brodehl J
Transplant Proc; 1996 Aug; 28(4):2259-61. PubMed ID: 8769218
[No Abstract] [Full Text] [Related]
4. Absorption of cyclosporine Neoral early after liver transplantation: influence of bile on oral absorption.
Oldhafer K; Haller GW; Kattner A; Winkler M; Maibücher A; Färber L; Bechstein WO; Ringe B; Neuhaus P; Pichlmayr R
Transplant Proc; 1996 Aug; 28(4):2237-8. PubMed ID: 8769210
[No Abstract] [Full Text] [Related]
5. Conversion from Sandimmune to Neoral in stable renal and pancreas transplant recipients enhances cyclosporine absorption.
Chapman JR; O'Connell PJ; Bovington KJ; Allen RD
Transplant Proc; 1996 Aug; 28(4):2293-5. PubMed ID: 8769229
[No Abstract] [Full Text] [Related]
6. Uses of Neoral in pediatric liver transplantation.
McDiarmid SV
Transplant Proc; 1996 Aug; 28(4):2264-6. PubMed ID: 8769220
[No Abstract] [Full Text] [Related]
7. Absorption of cyclosporine Neoral early after liver transplantation: is it possible to abandon intravenous cyclosporine A application?
Haller GW; Winkler M; Bechstein WO; Oldhafer KJ; Ringe B; Maibücher A; Färber L; Pichlmayr R; Neuhaus P
Transplant Proc; 1996 Aug; 28(4):2239-40. PubMed ID: 8769211
[No Abstract] [Full Text] [Related]
8. Pharmacokinetic analysis of Neoral conversion in pediatric and adult renal transplant recipients with poor absorption of Sandimmune.
Pescovitz MD; Henson S; Bodziak K; Book BK; Gonin J; Jindal RM; Leapman SB; Milgrom ML; Filo RS
Transplant Proc; 1996 Aug; 28(4):2165-8. PubMed ID: 8769189
[No Abstract] [Full Text] [Related]
9. Pharmacokinetics of a microemulsion formulation of cyclosporine in pediatric liver transplant recipients.
Cooney GF; Lum BL; Meligeni JA; Dunn SP
Transplant Proc; 1996 Aug; 28(4):2270-2. PubMed ID: 8769222
[No Abstract] [Full Text] [Related]
10. Conversion from Sandimmune to Neoral in stable heart transplant recipients.
Pethig K; Ruhparwar A; Korn A; Christians U; Wahlers T
Transplant Proc; 1996 Aug; 28(4):2287-9. PubMed ID: 8769228
[No Abstract] [Full Text] [Related]
11. Changing stable heart transplant recipients from Sandimmune to Neoral.
Dalrymple-Hay M; Meara M; Reynolds L; Backhouse L; Wright D; Holt D; Johnston A; Madden B; Murday A
Transplant Proc; 1996 Aug; 28(4):2285-6. PubMed ID: 8769227
[No Abstract] [Full Text] [Related]
12. Excessive cyclosporine trough level variation with classic cyclosporine can be reduced with the new oral microemulsion formulation of cyclosporine.
Bökenkamp A; Offner G; Hoyer PF; Wonigeit K; Brodehl J
Transplant Proc; 1996 Aug; 28(4):2273-5. PubMed ID: 8769223
[No Abstract] [Full Text] [Related]
13. Use of Neoral in pediatric renal transplantation.
Ettenger RE; Smith HT; Kaiser B; Cooney GF; Summerauer J; Alexander S; Moulton LT; Choc MG; Wong RL
Transplant Proc; 1996 Aug; 28(4):2257-8. PubMed ID: 8769217
[No Abstract] [Full Text] [Related]
14. The Swedish nationwide experience of converting transplant patients treated with Sandimmun to the new galenic formulation Sandimmun-neoral. The Swedish Sandimmun-Neoral Conversion Group.
Wilczek HE; Berglin E; Blohmé I; Bäckman L; Fehrman I; Källen R; Nyberg G; Säwe J; Wahlberg J
Transplant Proc; 1997; 29(1-2):280-3. PubMed ID: 9122995
[No Abstract] [Full Text] [Related]
15. Long-term results of conversion from existing to microemulsion formulation of cyclosporine.
Neumayer HH; Färber L; Budde K; Kohnen R; Maibücher A; Schuster A; Vollmar J; Waiser J; Luft FC
Transplant Proc; 1996 Aug; 28(4):2207-13. PubMed ID: 8769202
[No Abstract] [Full Text] [Related]
16. Cyclosporine pharmacokinetic profiles in stable renal allograft recipients converting from Sandimmun to Neoral.
Vathsala A; Lee WT; Jacob E; Woo KT
Transplant Proc; 1996 Jun; 28(3):1324-6. PubMed ID: 8658678
[No Abstract] [Full Text] [Related]
17. Cyclosporine pharmacology.
Lee JI; Canafax DM
Transplant Proc; 1996 Aug; 28(4):2156-8. PubMed ID: 8769185
[No Abstract] [Full Text] [Related]
18. Effect of conversion from Sandimmune to Neoral on glomerular filtration rate in stable renal transplant recipients.
Steinmuller D; Dougherty J; Coutee J; Surek D; Swies G; Lewis R
Transplant Proc; 1997; 29(1-2):298-9. PubMed ID: 9123005
[No Abstract] [Full Text] [Related]
19. Favourable clinical results of Sandimmun-Neoral in malabsorbing liver and heart transplant recipients.
Färber L; Maibücher A; Geissler F; Gutzler F; Wiesinger FO; Winkler M
Transplant Proc; 1994 Oct; 26(5):2988-93. PubMed ID: 7940944
[No Abstract] [Full Text] [Related]
20. Oral cyclosporine pharmacokinetics in pediatric renal and liver transplant recipients.
Cooney GF; Dunn SP; Kaiser B; Kulinsky AV; Mochon M; Heifets M
Transplant Proc; 1994 Oct; 26(5):2779-80. PubMed ID: 7940876
[No Abstract] [Full Text] [Related]
[Next] [New Search]
